| Title: | Triazolo Derivatives as Inhibitors of PDE10A | ||
| Patent/Patent Application Number: | WO 2013/178512 A1 | Publication Date: | December 5, 2013 |
| Priority Application: | EP 2012-1696954 | Priority Date: | May 30, 2012 |
| Inventors: | Flohr, A.; Groebke Zbinden, K.; Kuhn, B.; Lerner, C.; Rudolph, M.; Schaffhauser, H. | ||
| Assignee Company: | Hoffmann-La Roche Inc. | ||
| Disease Area: | CNS | Biological Target: | PDE10A |
| Summary: | The present application discloses a series of triazolo analogues capable of inhibiting the activity of PDE10A, a unique enzyme from the phosphodiesterase family. It is suggested that this enzyme plays a key role in various physiological functions and diseases that can be treated by PDE10A inhibitors including, but not limited to, certain psychotic and neurodegenerative disorders such as schizophrenia, acute stress disorder, drug addictions, obsessive/compulsive disorders, movement disorders, cognition deficiency disorders, and bipolar disorders. | ||
| Important Compound Classes: |  |
||
| Key Structures: |  |
||
| Recent Review Articles: | Menniti F. S.; Chappie T. A.; Humphrey J. M.; Schmidt C. J.. Curr. Opin. Invest. Drugs 2007, 8, 54–59. | ||
| Biological Assay: | Compound efficacy was evaluated using cAMP binding assay. | ||
| Pharmacological Data: |  |
||
| Synthesis: | 136 compounds were synthesized | ||
The authors declare no competing financial interest.